Ek Torben, Mellander Lotta, Hahn-Zoric Mirjana, Abrahamsson Jonas
Department of Pediatrics, Goteborg University, Goteborg, Sweden.
J Pediatr Hematol Oncol. 2004 Nov;26(11):727-34. doi: 10.1097/00043426-200411000-00008.
Immunity to diphtheria toxoid (D), tetanus toxoid (T), and Haemophilus influenzae type b (Hib) is affected in children with acute lymphoblastic leukemia (ALL). The aims were to examine immunity and to compare the response to immunization at 1 or 6 months after treatment.
Thirty-one patients were immunized with DT and conjugated Hib vaccine (ActHib) at 1 month or 6 months after treatment of ALL with the NOPHO 92 protocol. Antibody levels were determined before and 3 weeks after vaccination. Specific T and Hib antibody-secreting cells of IgG/IgA/IgM isotypes were analyzed in peripheral blood using an ELISPOT technique.
All specific antibody levels decreased during ALL treatment, and protective levels after treatment were noted for 17% against D, 33% against T, and 100% against Hib. No high-risk patient had full D or T protection after treatment. After vaccination all the standard- and intermediate-risk patients achieved full protection against D, T, and Hib. The high-risk group showed insufficient immune response (full protection after vaccination: D 56%, T 22%, Hib 78%). No difference was found between vaccination at 1 month or 6 months after treatment. The poor antibody production in the high-risk group correlated to low numbers of antibody-secreting cells.
Nonprotective antibody levels against D, T, and Hib after childhood ALL are more common than previously thought. Insufficient immune response was restricted to the high-risk group and was related to a low number of memory B cells in this study. Immunizations should be included in follow-up after childhood ALL, and the policy should be adapted to treatment intensity.
急性淋巴细胞白血病(ALL)患儿对白喉类毒素(D)、破伤风类毒素(T)和b型流感嗜血杆菌(Hib)的免疫力受到影响。本研究旨在检测免疫力,并比较治疗后1个月或6个月时免疫接种的反应。
31例ALL患者按照NOPHO 92方案治疗,在治疗后1个月或6个月接种DT和结合型Hib疫苗(ActHib)。在接种疫苗前和接种后3周测定抗体水平。采用ELISPOT技术分析外周血中IgG/IgA/IgM同种型的特异性T和Hib抗体分泌细胞。
在ALL治疗期间,所有特异性抗体水平均下降,治疗后具有保护水平的比例分别为:抗D为17%,抗T为33%,抗Hib为100%。治疗后,没有高危患者获得完全的D或T保护。接种疫苗后,所有标准风险和中危患者均获得了对D、T和Hib的完全保护。高危组显示免疫反应不足(接种疫苗后完全保护:D为56%,T为22%,Hib为78%)。治疗后1个月或6个月接种疫苗之间未发现差异。高危组抗体产生不佳与抗体分泌细胞数量少有关。
儿童ALL后抗D、T和Hib的非保护性抗体水平比以前认为的更常见。免疫反应不足仅限于高危组,在本研究中与记忆B细胞数量少有关。儿童ALL后的随访应包括免疫接种,且策略应根据治疗强度进行调整。